Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:WVE News 27 June 2025 - 3 February 2026

GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK shares edged up 0.1% to 1,926.5 pence Tuesday, nearing a one-year high ahead of its earnings report due Wednesday. The company is cutting about 350 R&D jobs in the UK and U.S. and recently returned rights to the WVE-006 drug candidate to Wave Life Sciences. Investors await CEO Luke Miels’ first major update and signals on cost controls and R&D priorities.
3 February 2026
····
Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences shares fell 6.7% to $13.84 Friday, underperforming biotech peers ahead of the J.P. Morgan Healthcare Conference. Investors are watching for CEO Paul Bolno’s Tuesday update on WVE-007, its obesity drug, after December’s interim data showed a 9.4% visceral fat reduction. The company recently raised $350 million in a public offering.
11 January 2026
··
Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now

Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now

Wave Life Sciences shares dropped 5.6% to $14.00 on Friday, underperforming biotech ETFs. The decline follows a $350 million stock offering and comes ahead of new obesity drug trial data expected later in 2026. Investors remain focused on dilution risks and upcoming updates from management. CEO Paul Bolno will present at the J.P. Morgan Healthcare Conference on January 13.
9 January 2026
·
Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences shares surged 17.2% to $17.58 Tuesday on heavy volume, after new data from Arrowhead Pharmaceuticals showed weight loss benefits from RNAi obesity drugs. Wave is developing a similar therapy, WVE-007, targeting the same gene. The company recently raised $402.5 million in a public offering. Investors await further trial results expected in early 2026.
6 January 2026
··
Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

Wave Life Sciences shares fell 6.2% to $15.95 Friday, underperforming the flat Nasdaq Biotechnology Index. The company expects more Phase 1 obesity trial data in Q1 2026. A December SEC filing said Wave’s equity raise, including over-allotments, was expected to bring in about $402.5 million. Early data showed WVE-007 reduced visceral fat by 9.4% at three months in a 32-person cohort.
4 January 2026
·
Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

New York, Dec. 26, 2025 (10:08 a.m. ET) — Wave Life Sciences Ltd. (NASDAQ: WVE) is trading at $18.12, down about 0.74% in the late morning session. The move comes while biotech is broadly softer—SPDR S&P Biotech ETF (XBI) is down about 1.07% and iShares Nasdaq Biotechnology ETF (IBB) is down about 0.63%—even as the broader market edges higher, with SPY and QQQ both modestly in the green. That “WVE down while the market is up” headline can look ominous—until you zoom out and remember what happened earlier this month: Wave’s stock ripped higher on early obesity data, then the
26 December 2025
··
Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences Ltd. (NASDAQ: WVE) is back in the spotlight on December 18, 2025—not because of a brand-new press release, but because the stock is still digesting one of the most volatile biotech weeks of the year. In Thursday trading, WVE stock fell roughly mid-single digits, hovering in the mid-$15 range after closing around $16.34 the prior session, according to market data and widely circulated market recaps. StockAnalysis+1 That pullback matters because it comes right after a dramatic early-December surge tied to Wave’s obesity program—and immediately following a large equity financing that materially changes the company’s cash position and
18 December 2025
Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

December 16, 2025 — Wave Life Sciences Ltd. (NASDAQ: WVE) is back in the spotlight after a roller-coaster week that mashed together three classic biotech ingredients: eye-popping early clinical data, a rapidly upsized stock offering, and a stack of Wall Street price-target hikes. As of 14:38 UTC on Tuesday (Dec. 16, 2025), Wave Life Sciences stock was trading at $16.94, up about 5.2% on the day, with an intraday range of $16.14 to $17.27, according to market data. What changed today: Oppenheimer raised its price target to $32 from $24 and reiterated an Outperform rating, pointing to what it called
16 December 2025
··
US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns

US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns

U.S. stocks closed mixed on Thursday, December 11, 2025, as a historic surge in the Dow clashed with a sharp tech sell‑off led by Oracle and a wave of brutal collapses in thinly traded micro‑caps. By the closing bell (4 p.m. ET), the Dow Jones Industrial Average was up roughly 1.3–1.4% and at a record high, while the S&P 500 edged about 0.1–0.2% higher. The Nasdaq Composite, however, slipped around 0.3–0.4%, dragged down by AI‑linked growth stocks.TradingView+2StockAnalysis+2 Under the surface, the real drama was in the top losers list, where failed drug trials, emergency capital raises, reverse stock splits and delisting threats combined into a textbook lesson on risk.
11 December 2025
····
Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Updated: December 11, 2025 – all figures and ratings as of publication; this article is for information only and is not investment advice. Key takeaways WVE stock today: from under‑the‑radar biotech to market spotlight Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical‑stage biotechnology company focused on RNA‑based medicines, has gone from relative obscurity to market headline in a matter of days. As of late trading on December 11, 2025, WVE shares change hands around $17.06, with an intraday high of $20.19 and low of $16.75 on heavy volume. That pullback comes after a spectacular multi‑session surge: In parallel, an insider
11 December 2025
···
Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More

Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More

As Wall Street wakes up on Tuesday, December 9, 2025, investors are still digesting a wild Monday session in which a handful of biotech and tech names exploded higher, even as the major indices finished in the red ahead of tomorrow’s pivotal Federal Reserve decision.Reuters+ 1 Because today’s regular trading session has only just begun, “today’s biggest gainers” in practice means the largest movers from Monday’s US session (Dec. 8) that are driving market conversation and premarket positioning on Dec. 9 . Below is a news-style roundup of those stocks, the catalysts behind the rallies, and what Wall Street is
9 December 2025
····
Most Active Stocks Today (December 9, 2025): Nvidia, Tesla, Wave Life Sciences and Confluent Lead a Fed-Focused Wall Street

Most Active Stocks Today (December 9, 2025): Nvidia, Tesla, Wave Life Sciences and Confluent Lead a Fed-Focused Wall Street

New York — December 9, 2025 US investors are crowding into a tight cluster of high-conviction themes today: artificial intelligence chips, blockbuster media and software deals, obesity drugs, and speculative AI small caps. Coming into Tuesday’s session (December 9), Wall Street is just off record highs. On Monday, the S&P 500 slipped about 0.3%, the Dow Jones Industrial Average fell roughly 0.4%, and the tech-heavy Nasdaq eased 0.1%, but all three remained within striking distance of their all-time peaks.The Times Leader+ 1 At the same time, traders are bracing for the Federal Reserve’s final policy decision of 2025, widely expected
9 December 2025
····
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences Ltd. (NASDAQ: WVE) has suddenly gone from sleepy small‑cap biotech to front‑page obesity contender. After unveiling striking Phase 1 data for its RNA obesity drug WVE‑007 on December 8, 2025, the stock rocketed roughly 147% to about $18.52 per share, pushing the company’s market cap to around $3.0 billion as of early December 9. MLQ At the same time, Wave launched a $250 million public equity offering, setting up a dramatically stronger balance sheet—but also introducing dilution right after the rally. GlobeNewswire Below is a detailed look at what just happened, why WVE stock is suddenly in
9 December 2025
···
Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences Ltd. (NASDAQ: WVE) just delivered one of the wildest biotech moves of 2025. On Monday, December 8, 2025, the stock rocketed after the company reported positive Phase 1 obesity drug data for WVE‑007 and simultaneously launched a $250 million equity offering. With the next U.S. trading session set to open on Tuesday, December 9, investors are trying to decide whether this is the beginning of a new obesity heavyweight—or a classic biotech spike that could retrace just as fast. Below is a concise, news-style wrap of everything that happened after the bell on December 8 and what
9 December 2025
··
Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

U.S. stocks traded mostly flat on Monday as Wall Street headed into a crucial Federal Reserve meeting, but under the surface the tape was anything but quiet. While the S&P 500 and Dow Jones Industrial Average hovered around unchanged and the Nasdaq 100 eked out a small gain, small‑cap and high‑beta names ripped higher, led by a wave of biotech catalysts and a blockbuster AI‑data takeover. According to StockAnalysis.com’s real‑time “Gainers Today” screen, Cemtrex, Structure Therapeutics, Wave Life Sciences, Fulcrum Therapeutics and iBio sat atop the leaderboard by early afternoon, each posting gains of nearly 50% or more. Many of
8 December 2025
········
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began a Phase I/II study in 2024, with initial first-in-human data expected in late 2025. Wave Life Sciences’ RNA base-editing drug WVE-006 showed proof-of-mechanism in humans in 2024, and multi-dose trial data are anticipated in 2025. In April 2025, the FDA approved Abeona Therapeutics’ Zevaskyn, the first cell-based gene therapy for the rare skin disorder RDEB, with launch planned in Q3
27 June 2025
···········

Stock Market Today

Intel stock (INTC) jumps to $50.59 — the two headlines traders will watch before Monday

Intel stock (INTC) jumps to $50.59 — the two headlines traders will watch before Monday

7 February 2026
New York, Feb 7, 2026, 15:53 ET — Market closed. Intel shares rose 4.87% on Friday to close at $50.59, snapping a two-session slide as U.S. stocks surged. Nvidia climbed 7.87% and Broadcom gained 7.22%, while the S&P 500 added 1.97% and the Dow rose 2.47%. (MarketWatch) With U.S. markets shut for the weekend, the question shifts to whether the bid holds into Monday as investors re-price the AI hardware trade after a volatile week. “There’s enough evidence that there’s real demand for AI products,” said Ross Mayfield, an investment strategy analyst at Baird. (Reuters) One reason Intel is back
RTX stock faces Pentagon payout curb list next week as dividend stays in play

RTX stock faces Pentagon payout curb list next week as dividend stays in play

7 February 2026
RTX closed at $198.66 Friday, up 1.4%, after declaring a 68-cent quarterly dividend payable March 19. The Pentagon is expected to name defense contractors early next week that could face limits on dividends and buybacks under a Trump order. RTX’s Raytheon unit has been singled out as “least responsive.” Companies named would have 15 days to submit remediation plans.
Go toTop